NfL

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis

Study Overview The research investigates the effects of ozanimod, an oral medication, on key biomarkers associated with neurodegeneration and inflammation

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis Read Post »

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics

Study Overview This research investigates protein alterations in the cerebrospinal fluid (CSF) using two distinct models of demyelination: Experimental Autoimmune

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics Read Post »

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology’s Study Group on Multiple Sclerosis and Related Neuroimmune Diseases

Relevance of Neurofilament Light Chain Neurofilament light chain (NfL) plays a crucial role in the assessment of neurodegenerative diseases, including

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology’s Study Group on Multiple Sclerosis and Related Neuroimmune Diseases Read Post »

Scroll to Top